Study summary
Mavacamten let most people avoid septal reduction surgery for over two years
15.7%went on to septal reduction or stayed eligible at 128 weeks
What was tested
Mavacamten for people with severe obstructive hypertrophic cardiomyopathy who had been referred for septal reduction surgery or ablation.
What they found
- Only 15.7% went on to septal reduction or remained eligible for it at 128 weeks.
- 80.5% improved by at least one NYHA class.
- 13.8% had a temporary drop in ejection fraction below 50%.
What it means
Shows myosin inhibitors can replace invasive procedures for many.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.